Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide dramatic antitumor activity in advanced non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the majority of patients treated with standard EGFR-TKIs frequently acquire resistance within 1 to 2 years [1 –4], and the most common mechanism is T790 M mutation [5–7]. Osimertinib is a third-generation EGFR-TKI that is selective for both EGFR-activating and T790 M mutations in NSCLC patients [8].

Source: Lung Cancer - November 1, 2019 Category: Cancer & Oncology Authors: Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Kazuto Hirata, Yasuhiro Koh, Tomoya Kawaguchi Source Type: research